---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-011960"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:53:00.785051+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lyell Q4 net loss $191.9M; cash $383.5M; IMPT-314 pivotal trials set for mid-2025, early 2026

## Summary
- Net loss of $191.9M in Q4 2024 included $87.2M acquired IPR&D from ImmPACT Bio and $51.3M long-lived asset impairment.
- Cash, equivalents and marketable securities of $383.5M at Dec 31, 2024; expected to fund operations into 2027.
- IMPT-314 Phase 1/2 showed 94% ORR (16/17) and 71% complete response by 3 months; no Grade 3+ CRS in 23 patients.
- Pivotal trial for IMPT-314 in 3rd line+ LBCL expected mid-2025; 2nd line pivotal expected by early 2026.
- Non-GAAP net loss Q4 2024 was $45.9M vs $43.9M in Q4 2023; full year 2024 non-GAAP net loss $159.5M.

## SEC filing metadata
- accession: 0001628280-25-011960
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828025011960/0001628280-25-011960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828025011960/lyel-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-011960
- JSON: https://secwatch.observer/filing/0001628280-25-011960.json
- Plain text: https://secwatch.observer/filing/0001628280-25-011960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.